Abstract 2082P
Background
Medical cannabis (MC) has garnered significant attention as a potential strategy for cancer care. Attitudes and beliefs of medical professionals regarding its efficacy and safety remain diverse and inconclusive. This survey explores medical professionals' knowledge, attitudes, and barriers towards MC for cancer care. It aims to understand their beliefs on efficacy and safety, benefits and risks, and identify barriers to its use.
Methods
175 medical professionals worldwide completed a 31-item survey that included demographics, knowledge and attitudes towards MC, perceived benefits and risks, and willingness to recommend MC to patients. Data analysis involved descriptive statistics and Chi-square tests.
Results
The survey included respondents with a balanced male-to-female ratio and a median age of 37 years from 31 countries, with 120 from upper-middle-income countries (UMIC) and 55 from lower-middle-income countries (LMIC). Findings revealed that 44% of respondents were familiar with MC, and 51% claimed to have received information about it from patients, with 35% receiving direct prescription requests. Surprisingly, only 16% had prescribed MC for symptoms such as CINV, pain, anorexia, cachexia, psychiatric symptoms, insomnia, muscle spasms. There were no significant associations between knowledge levels or patient prescription requirements and income level, but a significant association was found between drug prescription and UMICs. (p = 0.003). Notably, only 9% of participants were knowledgeable about their country's MC legislation, although most believed that legislative and social stigma posed significant barriers to its use.
Conclusions
The survey revealed significant variations in the knowledge and attitudes of medical oncologists towards MC in cancer care. Geographic differences were also observed, with professionals from UMICs more inclined to prescribe MC. These findings underscore the need for enhanced education and training for medical professionals regarding the use of MC in cancer care, thereby informing future research and clinical practices in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06